论文部分内容阅读
为了探讨复方肿瘤血管生成抑制因子口服液（ＣＯＬ－ＴＡＩ）对动物及人体的一般毒性和遗传毒性，采用动物急性毒性试验、动物慢性毒性试验、小鼠骨髓嗜多染红细胞微核实验和人体外周血淋巴细胞体外培养染色体畸变实验，观察ＣＯＬ－ＴＡＩ的一般毒性和遗传毒性．结果显示：ＣＯＬ－ＴＡＩ对小鼠的急性毒性试验表明，该药口服途径的ＬＤ５０为９．１２０１ｇｋｇ－１（７．７６６ｇ～１０．７０９１ｇｋｇ－１）；慢性毒性试验显示该口服液对内脏各器官和生理指标均无任何蓄积毒性和延迟毒性反应作用；ＣＯＬ－ＴＡＩ对小鼠骨髓微核和人外周血淋巴细胞染色体畸变等均无诱变作用，ＣＯＬ－ＴＡＩ可降低环磷酰胺（ＣＴＸ）对受试动物细胞微核的发生率．ＣＯＬ－ＴＡＩ无毒，对化学法突变剂引起的微核产生有抑制作用，对染色体损伤有一定的保护作用．
In order to investigate the general toxicity and genotoxicity of compound tumor angiogenesis inhibitor oral liquid (COL-TAI) to animals and human beings, the animal acute toxicity test, animal chronic toxicity test, mouse bone marrow polychromatic erythrocyte micronucleus test and human peripheral Chromosome aberration test of blood lymphocytes cultured in vitro was conducted to observe the general toxicity and genotoxicity of COL-TAI. The results showed that the acute toxicity test of COL-TAI in mice showed that the LD50 of the oral route of the drug was 9.1201gkg-1 (7.766g-10.7091gkg-1). The chronic toxicity test showed that the oral liquid had a good effect on visceral organs And physiological indicators did not accumulate any toxic effects and delayed the toxic reaction; COL-TAI on mouse bone marrow micronuclei and human peripheral blood lymphocyte chromosome aberrations were not mutagenic, COL-TAI can reduce cyclophosphamide (CTX) The incidence of micronucleus in the animal cells tested. COL-TAI non-toxic, chemical mutagen-induced micronucleus production inhibition, chromosome damage have a protective effect.